Photo by Pixabay on Pexels.com
KUALA LUMPUR — MBSB Research has maintained a POSITIVE outlook on the healthcare sector following strong 4QFY25 earnings in the US and Europe, driven largely by pharmaceuticals. Demand for GLP-1 drugs, used in diabetes and obesity treatment, lifted pharmaceutical performance, while US hospitals reported resilient inpatient volumes despite labour shortages.
Medical devices and equipment also saw higher demand for high-margin treatments, with oncology drugs adding further momentum. Malaysian healthcare players are expected to mirror global trends, supported by medical tourism, government initiatives to reduce medical costs, recovery in the glove sector, and growth in the halal pharmaceutical market. These factors provide additional upside, positioning Malaysia’s healthcare industry for sustained expansion in 2026.
Read More News on Latest Malaysia
Read More News on Business News Malaysia
Read More News on SG Business News
Read More News on World Future TV
Government expands Budi Diesel quota to 300 litres monthly, aiding 200,000 pick‑up and jeep owners;…
Paris Baguette Malaysia is now fully integrated under Singapore HQ, enhancing operations and regional strategy…
Malaysian enterprises must modernize infrastructure strategically to harness AI, enhancing resilience and reducing costs effectively.
Vertiv opened its Johor manufacturing facility to expand AI infrastructure production, strengthen regional supply chains,…
Malaysia's manufacturing sector returned to expansion in June as stronger orders and production lifted PMI…
Southern Cable secured a RM403.6 million TNB contract extension, lifting its order book above RM1…
This website uses cookies.